John Persinos

John Persinos is an editorial manager at Investing Daily. John previously served as a staff reporter on daily metropolitan newspapers, including The Orlando (Fla.) Sentinel. He also has worked on several magazines, specifically as a staff writer at Inc.; an associate editor at Venture; and managing editor at Campaigns & Elections. He also has served as an online publisher of Web sites, including Aviation Today. Persinos has written extensively for investment-oriented publications and Web sites, such as Kiplinger's Personal Finance magazine, StreetAuthority, Investing Answers, The Street Report, and InvestorPlace. During his tenure as its editorial director, Personal Finance newsletter won Best Financial/Investing Newsletter from the Specialized Information Publishers Association (SIPA) in 2014. Persinos holds a B.A. in english, an M.A. in english literature, and an M.S. in journalism, all from Boston University. He also completed the Davenport Fellowship in Business and Economics Reporting at the University of Missouri (Columbia) School of Journalism.

Recent Articles By The Author

Brexit, Schmexit: Bet on Europe With This Resilient Consumer Stock

Brexit, Schmexit: Bet on Europe With This Resilient Consumer Stock

Britain's exit from the European Union will have many casualties, but this international purveyor of beloved consumer brands should be just fine.

Turn to the 'Cisco Kid' to Win Today's Political Battles

Turn to the 'Cisco Kid' to Win Today's Political Battles

Investors are nervously eyeing the growing chaos in the White House and overseas. Here's a tech stock that combines growth and safety, with powerful trends in its favor.

Seadrill's Stock Is Getting Thrashed by a Shocking Amount - Its Future Now Looks Doomed

Seadrill's Stock Is Getting Thrashed by a Shocking Amount - Its Future Now Looks Doomed

Seadrill's stock is in free fall, with scant chance of recovery. Here's why it could drop to zero.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Here's Why It May Be Time to 'Short' Vladimir Putin

Here's Why It May Be Time to 'Short' Vladimir Putin

The Russian president's interference in Western affairs will likely come back to haunt his country's already hobbled economy. Get into position with this ETF.

The Yuuuge Trumpcare Defeat Means Little to This Drug Retailing Giant

The Yuuuge Trumpcare Defeat Means Little to This Drug Retailing Giant

The lurid spectacle of Trumpcare's collapse shocked the political and health services establishments, but this drug retailer continues apace on its profit-making path.

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Annuities are in the news as Trump's appointee to head the Department of Labor spars with Sen. Warren. Here's what investors need to know.

Week Ahead: The GOP Girds for Battle ... With Itself

Week Ahead: The GOP Girds for Battle ... With Itself

Wall Street's pro-business agenda could suffer collateral damage, as infighting among Republicans grows worse. Here's how to trade in the days ahead.

How to Make Some Bread as Panera Follows Amazon's Lead

How to Make Some Bread as Panera Follows Amazon's Lead

The bakery-café has announced it will begin offering delivery service from all of its locations. Here's why investors should order up.

As the Russian Hacking Scandal Worsens, This Tech Stock Should Get a Lift

As the Russian Hacking Scandal Worsens, This Tech Stock Should Get a Lift

The Trump Team is under growing scrutiny for its potential complicity in election-year cyber attacks, which brings this tech company's specialty to the fore.